After “issues” with a batch of its investigational antibody briquilimab “confounded” the readout of Jasper Therapeutics’ Phase Ib/IIa BEACON study in chronic spontaneous urticaria (CSU), the California-based biotech is laying off approximately half of its staff.
All entries for: Jasper Therapeutics
July 9, 2025
Jasper Therapeutics
Layoffs
Redwood City, CA
51-200 employees
Disease Area: Chronic Disease, Hematology, Immune Diseases, Multiple
Drug Type: Biologic